These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 37240327)
1. Enzymatic Deglycation of Damaged Skin by Means of Combined Treatment of Fructosamine-3-Kinase and Fructosyl-Amino Acid Oxidase. De Decker I; Notebaert M; Speeckaert MM; Claes KEY; Blondeel P; Van Aken E; Van Dorpe J; De Somer F; Heintz M; Monstrey S; Delanghe JR Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240327 [TBL] [Abstract][Full Text] [Related]
2. Fructosyl Amino Oxidase as a Therapeutic Enzyme in Age-Related Macular Degeneration. Delanghe JR; Diana Di Mavungu J; Beerens K; Himpe J; Bostan N; Speeckaert MM; Vrielinck H; Vral A; Van Den Broeke C; Huizing M; Van Aken E Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732004 [TBL] [Abstract][Full Text] [Related]
3. A Potential Role for Fructosamine-3-Kinase in Cataract Treatment. De Bruyne S; van Schie L; Himpe J; De Somer F; Everaert I; Derave W; Van den Broecke C; Huizing M; Bostan N; Speeckaert M; Callewaert N; Van Aken E; Delanghe JR Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917258 [TBL] [Abstract][Full Text] [Related]
4. Intrinsic toxicity of glucose, due to non-enzymatic glycation, is controlled in-vivo by deglycation systems including: FN3K-mediated deglycation of fructosamines and transglycation of aldosamines. Szwergold BS Med Hypotheses; 2005; 65(2):337-48. PubMed ID: 15922110 [TBL] [Abstract][Full Text] [Related]
5. A Hypothesis: Fructosamine-3-Kinase-Related-Protein (FN3KRP) Catalyzes Deglycation of Maillard Intermediates Directly Downstream from Fructosamines. Szwergold B Rejuvenation Res; 2021 Aug; 24(4):310-318. PubMed ID: 34314247 [TBL] [Abstract][Full Text] [Related]
7. Evidence That Differences in Fructosamine-3-Kinase Activity May Be Associated With the Glycation Gap in Human Diabetes. Dunmore SJ; Al-Derawi AS; Nayak AU; Narshi A; Nevill AM; Hellwig A; Majebi A; Kirkham P; Brown JE; Singh BM Diabetes; 2018 Jan; 67(1):131-136. PubMed ID: 29066600 [TBL] [Abstract][Full Text] [Related]
8. Enzymatic deglycation--a new paradigm or an epiphenomenon? Szwergold BS; Beisswenger PJ Biochem Soc Trans; 2003 Dec; 31(Pt 6):1428-32. PubMed ID: 14641081 [TBL] [Abstract][Full Text] [Related]
9. Fructosamine-3-kinase-related-protein phosphorylates glucitolamines on the C-4 hydroxyl: novel substrate specificity of an enigmatic enzyme. Szwergold B; Manevich Y; Payne L; Loomes K Biochem Biophys Res Commun; 2007 Oct; 361(4):870-5. PubMed ID: 17686456 [TBL] [Abstract][Full Text] [Related]
11. Fructosamine-6-phosphates are deglycated by phosphorylation to fructosamine-3,6-bisphosphates catalyzed by fructosamine-3-kinase (FN3K) and/or fructosamine-3-kinase-related-protein (FN3KRP). Szwergold BS Med Hypotheses; 2007; 68(1):37-45. PubMed ID: 16920277 [TBL] [Abstract][Full Text] [Related]
12. The fructosamine 3-kinase knockout mouse: a tool for testing the glycation hypothesis of intracellular protein damage in diabetes and aging. Monnier VM Biochem J; 2006 Oct; 399(2):e11-3. PubMed ID: 16987105 [TBL] [Abstract][Full Text] [Related]
13. Many fructosamine 3-kinase homologues in bacteria are ribulosamine/erythrulosamine 3-kinases potentially involved in protein deglycation. Gemayel R; Fortpied J; Rzem R; Vertommen D; Veiga-da-Cunha M; Van Schaftingen E FEBS J; 2007 Sep; 274(17):4360-74. PubMed ID: 17681011 [TBL] [Abstract][Full Text] [Related]
14. Fructosamine-3-Kinase as a Potential Treatment Option for Age-Related Macular Degeneration. De Bruyne S; Van den Broecke C; Vrielinck H; Khelifi S; De Wever O; Bracke K; Huizing M; Boston N; Himpe J; Speeckaert M; Vral A; Van Dorpe J; Van Aken E; Delanghe JR J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899850 [TBL] [Abstract][Full Text] [Related]
15. Topical Application of Deglycating Enzymes as an Alternative Non-Invasive Treatment for Presbyopia. Delanghe JR; Beeckman J; Beerens K; Himpe J; Bostan N; Speeckaert MM; Notebaert M; Huizing M; Van Aken E Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108506 [TBL] [Abstract][Full Text] [Related]
16. Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo. Szwergold BS; Howell S; Beisswenger PJ Diabetes; 2001 Sep; 50(9):2139-47. PubMed ID: 11522682 [TBL] [Abstract][Full Text] [Related]
17. Possible role of fructosamine 3-kinase genotyping for the management of diabetic patients. Avemaria F; Carrera P; Lapolla A; Sartore G; Chilelli NC; Paleari R; Ambrosi A; Ferrari M; Mosca A Clin Chem Lab Med; 2015 Aug; 53(9):1315-20. PubMed ID: 26352355 [TBL] [Abstract][Full Text] [Related]
18. Enzymatic repair of Amadori products. Van Schaftingen E; Collard F; Wiame E; Veiga-da-Cunha M Amino Acids; 2012 Apr; 42(4):1143-50. PubMed ID: 20967558 [TBL] [Abstract][Full Text] [Related]
19. Identification of fructosamine residues deglycated by fructosamine-3-kinase in human hemoglobin. Delpierrre G; Vertommen D; Communi D; Rider MH; Van Schaftingen E J Biol Chem; 2004 Jun; 279(26):27613-20. PubMed ID: 15102834 [TBL] [Abstract][Full Text] [Related]
20. Effects of fructosamine-3-kinase deficiency on function and survival of mouse pancreatic islets after prolonged culture in high glucose or ribose concentrations. Pascal SM; Veiga-da-Cunha M; Gilon P; Van Schaftingen E; Jonas JC Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E586-96. PubMed ID: 20009024 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]